NG-497 Alleviates Microglia-Mediated Neuroinflammation in a MTNR1A-Dependent Manner
Inflammation · 2025
DOI: 10.1007/s10753-024-02218-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammation, 2025. Verfasst von Qi Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Microglia, Neuroinflammatory Diseases, Receptor, Melatonin, MT1, Anti-Inflammatory Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Microglia-mediated neuroinflammation plays a crucial role in multiple neurological diseases. We have previously found that Atglistatin, the mouse Adipose Triglyceride Lipase (ATGL) inhibitor, could promote lipid droplets (LDs) accumulation and suppress LPS-induced neuroinflammation in mouse microglia. However, Atglistatin was species-selective, which limited its use in clinical settings. Here, we found that NG-497, a previously identified human ATGL inhibitor, significantly increased LDs accumulation and inhibited LPS-induced pro-inflammatory responses in human microglia. Moreover, NG-497 also protected human neurons against neurotoxic cytokines in a humanized in vitro model of neuroinflammation. However, the anti-inflammatory capacity of NG-497 was independent of its effect on ATGL. Instead, we revealed that NG-497 alleviated microglia-mediated neuroinflammation through elevating the protein level of melatonin receptor 1A (MTNR1A). Therefore, in this study, we uncovered a novel MTNR1A-targeting compound, which exhibited anti-inflammatory and neuroprotective effect, highlighting its potential in the treatment of neuroinflammation. Moreover, the MTNRs agonist, Ramelteon, exerts comparable anti-inflammation effects with NG-497.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- State Key Laboratory of Pharmaceutical Biotechnology and Institute of Translational Medicine for Brain Critical Diseases, Nanjing University, Nanjing, China.
- Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. xuyun20042001@aliyun.com.
- State Key Laboratory of Pharmaceutical Biotechnology and Institute of Translational Medicine for Brain Critical Diseases, Nanjing University, Nanjing, China. xuyun20042001@aliyun.com.
- Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing, China. xuyun20042001@aliyun.com.
- Nanjing Neurology Clinical Medical Center, Nanjing, China. xuyun20042001@aliyun.com.
Zitieren
APA
Li, Q., Liu, P., Zhu, X., Zhou, C., Hu, Y., Cao, S., Li, H., Zou, X., Gao, S., Cao, X., Bao, X., Xu, Y., & Li, J. (2025). NG-497 Alleviates Microglia-Mediated Neuroinflammation in a MTNR1A-Dependent Manner. Inflammation. https://doi.org/10.1007/s10753-024-02218-9
Vancouver
Li Q, Liu P, Zhu X, Zhou C, Hu Y, Cao S, et al. NG-497 Alleviates Microglia-Mediated Neuroinflammation in a MTNR1A-Dependent Manner. Inflammation. 2025. doi:10.1007/s10753-024-02218-9
BibTeX
@article{Li2025,
author = {Li, Qi and Liu, Pinyi and Zhu, Xuan and Zhou, Chao and Hu, Yujie and Cao, Shiying and Li, Huiya and Zou, Xinxin and Gao, Shenghan and Cao, Xiang and Bao, Xinyu and Xu, Yun and Li, Jingwei},
title = {NG-497 Alleviates Microglia-Mediated Neuroinflammation in a MTNR1A-Dependent Manner},
journal = {Inflammation},
year = {2025},
doi = {10.1007/s10753-024-02218-9}
}
EUVIMED